1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
1 citations
,
November 2005 in “Journal of Andrology” The meeting highlighted promising genetic treatments for male fertility issues but noted concerns about certain cancer risks and ICSI safety.
1 citations
,
January 2004 in “The Internet Journal of Geriatrics and Gerontology” Male pattern baldness is common, treatable, and may be linked to heart disease and prostate cancer.
1 citations
,
May 2001 in “Pharmacology & Toxicology” Cyproterone acetate may cause liver cancer at high doses, but is considered safe at recommended doses for approved uses.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
March 2026 in “European Urology Focus” Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.
July 2025 in “Journal of Education Health and Sport” Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
September 2024 in “The Scientific Issues of Ternopil Volodymyr Hnatiuk National Pedagogical University Series pedagogy” High uric acid can cause health problems, but lifestyle changes can help manage it.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
May 2021 in “The FASEB Journal” The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.
Increased free testosterone can lead to stronger bones and less body fat but also higher risks of prostate cancer, hair loss, spine issues, and high blood pressure.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
June 2017 in “Journal of The American Academy of Dermatology” Most men with lichen planopilaris had it confirmed by biopsy and often had thyroid issues, sexual dysfunction, or prostate cancer, hinting at a link with hormonal problems.
September 2016 in “Princeton University Press eBooks” The document concludes that understanding health requires considering evolutionary perspectives on reproductive fitness, and recognizing the complexity of factors like diet, testosterone, and sexual orientation.
October 2015 in “Prostate Cancer” Finasteride and dutasteride reduce prostate cancer risk, but finasteride may increase higher-grade cancer risk.
March 2015 in “Oncology Times” Extending androgen suppression before radiotherapy offers no extra survival benefit for intermediate-risk prostate cancer.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
September 2012 in “African Journal of Urology” Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.
April 2012 in “The Journal of Urology” Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
January 2012 in “International Society of Hair Restoration Surgery” Finasteride is effective for hair loss but has controversial side effects.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.